Jannatul Ferdoush

Dr. Jannatul Ferdoush

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
PPPuja Palit
Puja Palit
MMMaya M Minkara
Maya M Minkara
MAMaisha Abida
Maisha Abida
SMSafa Marwa
Safa Marwa
CSChandrima Sen
Chandrima Sen
JFJannatul Ferdoush
Jannatul Ferdoush
Plastic pollution has become a significant environmental issue worldwide, with global plastic production expected to reach 1800 million tons by 2050. One of the most commonly used plastics in the world is polyethylene terephthalate (PET), a synthetic polymer that is extremely durable but difficult to degrade. Thus, PET is dangerous to human health. To address this crisis, innovative approaches are being developed, including genome editing technologies. One of the recently advanced genome editing technologies is PlastiCRISPR, a novel concept that applies CRISPR-based genome editing to transform plastic waste management. PlastiCRISPR utilizes microorganisms to degrade plastic, generating valuable bioproducts like biofuels and biochemicals. Thus, this technology offers a sustainable solution because of its simple design, adequacy, and low cost, which can be integrated into existing waste management systems. Importantly, this review focuses on the PlastiCRISPR-based management of PET because it could drastically lower plastic waste, sustain natural resources by decreasing the requirement for plastic production, minimize energy intake, etc. Overall, this review provides an overview of the principles, applications, challenges, and future prospects of PlastiCRISPR in combating plastic pollution and shaping a more sustainable future.

23 May 2024 in Gene
Verified
Journal Article
Closed access
JFJannatul Ferdoush
Jannatul Ferdoush
RKRizwaan Abdul Kadir
Rizwaan Abdul Kadir
MOMatthew Ogle
Matthew Ogle
ASAyan Saha
Ayan Saha

11 July 2025 in Kinases and Phosphatases
Verified
Journal Article
Open access
PDF file
ASAyan Saha
Ayan Saha
EWEmily Wood
Emily Wood
LOLuna Omeragic
Luna Omeragic
MMMaya M Minkara
Maya M Minkara
Kethain MarmaKethain Marma
Kethain Marma
JFJannatul Ferdoush
Jannatul Ferdoush
Non-alcoholic fatty liver disease (NAFLD) is a common metabolic condition characterized by hepatic lipid deposits, insulin resistance, and inflammation which may progress to non-alcoholic steatohepatitis (NASH) and fibrosis. Protein kinases play an important role in NAFLD development by regulating metabolic and inflammatory pathways. Mitogen-activated protein kinases (MAPKs), protein kinase C (PKC), AMP-activated protein kinase (AMPK), phosphoinositide 3-kinase (PI3K)/AKT, and mechanistic target of rapamycin (mTOR) are all involved in NAFLD and NASH progression. Emerging evidence indicates that Farnesoid X Receptor (FXR) agonists have therapeutic potential by modulating bile acid metabolism, lipid balance, and inflammatory responses. This review examines the mechanistic interplay between FXR agonists and important protein kinases in NAFLD and NASH. FXR agonists activate AMPK, which promotes fatty acid oxidation and reduces hepatic steatosis. They also regulate MAPK signaling, which reduces c-Jun NH2-terminal kinase (JNK)- and p38 MAPK-mediated inflammation. Furthermore, FXR agonists activate the PI3K/AKT pathway, enhancing insulin sensitivity and modulating mTOR signaling to reduce hepatic fibrosis. Clinical studies in NAFLD/NASH indicate that FXR agonists confer metabolic and anti-inflammatory benefits, although optimizing efficacy and minimizing adverse effects remain challenging. Future studies should focus on combination therapies targeting FXR alongside specific kinases to improve therapeutic outcomes. This review highlights the potential of FXR agonists to modulate protein kinase signaling, opening new avenues for targeted NAFLD/NASH therapy.

13 March 2024 in Gene
Verified
Journal Article
Closed access
JFJannatul Ferdoush
Jannatul Ferdoush
RKRizwaan Abdul Kadir
Rizwaan Abdul Kadir
SKSelin Simay Kaplanoglu
Selin Simay Kaplanoglu
MOMorgan Osborn
Morgan Osborn

22 April 2025 in Journal of Genetic Engineering and Biotechnology
Verified
Journal Article
Open access
MTMaisha Tasneem
Maisha Tasneem
SGShipan Das Gupta
Shipan Das Gupta
JJJubair Ahmed Jony
Jubair Ahmed Jony
MMMaya M Minkara
Maya M Minkara
RDRajib Kumar Dey
Rajib Kumar Dey
JFJannatul Ferdoush
Jannatul Ferdoush
Liver Hepatocellular Carcinoma (LIHC) and Kidney Renal Clear Cell Carcinoma (KIRC) are leading causes of cancer death worldwide, but their early detections remain hindered by a lack of genetic markers. Our study aims to find prospective biomarkers that could serve as prognostic indicators for efficient drug candidates for KIRC and LIHC treatment. To detect differentially expressed genes (DEGs), four datasets were used: GSE66271 and GSE213324 for KIRC, and GSE135631 and GSE202853 for LIHC. Visualization of DEGs was done using heatmaps, volcano plots, and Venn diagrams. Hub genes were identified via PPI analysis and the cytoHubba plugin in Cytoscape. Their expression was evaluated using box plots, stage plots, and survival plots for prognostic assessment via GEPIA2. Molecular docking with PyRx's AutoDock Vina identified optimal binding interactions between compounds and proteins. Pharmacokinetic and toxicity analyses reinforced the drug-likeness and safety of these compounds. In this study, 47 DEGs were identified, with the top 10 hub genes being TOP2A, BUB1, PTTG1, CCNB2, NUSAP1, KIF20A, BIRC5, RRM2, NDC80 and CDC45, chosen for their high MCC scores. Data mining revealed a correlation between TOP2A expression and clinical survival outcomes in KIRC and LIHC patients. Docking studies of the TOP2A structure identified a promising compound from Andrographis paniculata with high binding energy and interactions with TOP2A. Pharmacokinetic and toxicity assessments support its potential as a drug candidate. Our study emphasizes TOP2A's prognostic significance in KIRC and LIHC and recognizes Andrographis paniculata compound as potential therapeutics, offering prospective for enhanced treatment and patient outcomes in these cancers.

4 June 2025 in Journal of Genetic Engineering and Biotechnology
Verified
Journal Article
Open access
ASAyan Saha
Ayan Saha
SSSenzuti Sharmin
Senzuti Sharmin
TATazin Ahmed
Tazin Ahmed
STSadia Tabassum
Sadia Tabassum
ARAyan Roy
Ayan Roy
JFJannatul Ferdoush
Jannatul Ferdoush
Kidney Renal Clear Cell Carcinoma (KIRC) is a leading cause of cancer death worldwide, but its early detection remains hindered by a lack of genetic markers. Our study aims to find prospective biomarkers that could serve as prognostic indicators and help in the identification of efficient drug candidates for KIRC treatment. Importantly, this study identifies the hub genes that play a crucial role in KIRC and their impact on male and female patients. The cBioPortal was used to identify frequently mutated genes across seven KIRC studies. Additionally, GSE168845 was employed to identify the differentially expressed genes. The analysis revealed that the titin (TTN) gene was mutated and upregulated in KIRC. Subsequently, differential genes of wild-type TTN versus mutant TTN were identified using TNMplot. The NetworkAnalyst tool was used to conduct KEGG analysis and PPI analysis on these genes. Furthermore, the Kaplan-Meier Plotter was utilized to perform overall survival analysis. Our findings indicated that the TTN gene leads to poorer prognosis in women than in men. We also discovered that the female-specific prolactin signaling pathway plays a significant role in the progression of KIRC. Moreover, our study suggested that the GDF15 gene, involved in the prolactin signaling pathway, has a worse prognosis for KIRC in women than in men. Additionally, mRNA expression analysis showed a negative correlation between GDF15 and MAPK14 in KIRC. Collectively, our research indicates that TTN, GDF15, and MAPK14 can serve as prognostic biomarkers in female KIRC patients, offering prospects for enhanced treatment and patient outcomes in these cancers.